Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia | Aplastic Anemia & MDS International Foundation
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Clinical Trial: NCT02845596

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this study is to determine the feasibility of comparing outcomes of patients treated de novo with immunosuppressive therapy (IST) versus matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT) for pediatric acquired severe aplastic anemia.

 

Status: 
Recruiting
Study Date: 
Wed, 07/27/2016 to Fri, 05/01/2020
Bone Marrow Disease(s): 
  • aplastic anemia
Intervention: 
Drug: cyclosporine Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant Drug: horse anti-thymocyte globulin (ATG) Drug: rabbit anti-thymocyte globulin (ATG) Drug: methotrexate Drug: fludarabine Drug: cyclophosphamide Radiation: low-dose total body irradiation (TBI) Procedure: Immunosuppressive Therapy (IST)